Proton pump inhibitor use associated with changes in gut microbiota composition
We read with great interest the recent publications in Gut by Imhann et al and Jackson et al, which assessed the impact of proton pump inhibitor (PPI) use on gut microbiota diversity and composition in humans. 1 2 PPIs are one of the most commonly used drug classes worldwide. Once initiated, they are often used chronically without clear therapeutic intent. 3 PPIs alter GI pH 4 and delay gastric emptying rate, 5 which could directly affect gut microbiota and survival of enteric pathogens. Using three independent cohorts (211 PPI users and 1604 non-users), Imhann et al 1 reported a significant decrease in alpha diversity and changes in 20% of bacterial taxa in PPI users compared with non-users.
Among 1827 healthy twins, Jackson et al 2 also found a significant decrease in alpha diversity and alteration of bacterial composition in PPI users. Notably, both studies found a higher abundance of oral commensals, including Streptococcaceae, among PPI users. These studies controlled for some potential confounders in their analyses; however, intersubject variability could have influenced their results.
We assessed the impact of PPI use on the gut microbiota composition in a prospective study of healthy older adults (age ≥60 years) from San Antonio, Texas, USA. Participants provided a stool sample at baseline, completed a 14-day course of omeprazole 20 mg daily and then provided a follow-up stool sample. Stool 16 s rRNA V4 sequences were amplified and sequenced on the Illumina MiSeq platform. Sequences were clustered into operational taxonomic units (OTUs) and classified via mothur's Bayesian classifier referenced against the Greengenes database. Abundance-weighted sample differences were calculated using the Bray-Curtis dissimilarity. PERMANOVA was used to assess the impact of PPI use on beta diversity.
A total of 24 subjects completed the study (mean age 71.4 years and 62.5% women). Mean (±SD) OTU richness was similar between pre-PPI (485±84.3) and post-PPI (496±88.7) samples (p=0.32). Additionally, Shannon diversity was not statistically different between pre-PPI (3.86±0.27) and post-PPI (3.92±0.31) 6 whereas supplementation with Bifidobacterium is associated with reduced risk of developing CDI in humans. 7 Similarly, the abundance of Streptococcaceae is significantly increased in CDI, while Lachnospiraceae are reduced compared with healthy controls. 8 While studies have been somewhat inconsistent, a 2012 meta-analysis of 42 studies found that PPI use was associated with an increased risk for initial and recurrent CDI. 9 This led the US Food and Drug Administration to issue a drug safety warning in 2012 regarding this association. Changes in gut microbiota composition could help explain this association. Our findings, in addition to those of Imhann et al and Jackson et al, highlight the potential for PPIs to affect health through alteration of the gut microbiota and the need to limit inappropriate and unnecessary use of PPIs. 
